Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2780103 | 0.98 | HTR2C (0.38) | HTR2CHTR2AHTR2BDRD2OPRM1 | |
| SCHEMBL28691096 | 0.89 | OPRM1 (0.39) | OPRM1HDAC6CTSLPROKR1KDM1A | |
| SCHEMBL6962020 | 0.86 | HTR2C (0.40) | HTR2CHTR2AHTR2BDRD2OPRM1 | |
| SCHEMBL7532775 | 0.84 | HTR2C (0.37) | HTR2CHTR2AHDAC6 | |
| SCHEMBL30596331 | 0.84 | HTR2C (0.37) | HTR2CHTR2AHDAC6 | |
| Hydrochloric Acid SCHEMBL29995070 | 0.83 | HTR2C (0.36) | HTR2CHDAC6 | |
| Hydrochloric Acid SCHEMBL7874218 | 0.83 | HTR2C (0.36) | HTR2CHDAC6 | |
| SCHEMBL17543073 | 0.80 | PSEN1 (0.42) | OPRM1HDAC6CTSLPROKR1CTSS | |
| SCHEMBL29087329 | 0.79 | HTR2C (0.36) | HTR2CKDM1A | |
| SCHEMBL17543855 | 0.79 | BACE1 (0.36) | HTR2CHTR2AHTR2BOPRM1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102239158-A | Method for preparing a spiroindoline and a precursor thereof | GLAXO GROUP LTD | 2011-11-09 | — | — | CN | claimed |
| EP-2370423-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Glaxo Group Limited (GB) | 2011-10-05 | — | — | EP | claimed |
| US-20110230660-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Method for Preparing a Spiroindoline | 2011-09-22 | — | — | US | claimed |
| WO-2010065704-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | claimed |
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-20110034499-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-7723350-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2010-05-25 | — | — | US | disclosed |
| EP-2166848-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157741-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR10, CXCR2 | HTR2C 961/4885HTR2A 572/4885HTR2B 805/4885 |
| US-20110034499-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR10, CXCR2 | HTR2C 961/4885HTR2A 572/4885HTR2B 805/4885 |
| US-20110230660-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | CCR2, CXCR4, CXCR2 | HTR2C 339/4885HTR2A 616/4885HTR2B 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.